Clinical trial · Interventional
Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Trial futility
Summary
Brief summary (as posted)
Lung resections for pulmonary malignancies offer the best chance of survival for patients, but these procedures carry a significant burden of post-operative morbidity and mortality. Patients are particularly at high risk for post-operative atrial fibrillation (a condition involving irregular heart rhythm). Atrial fibrillation with symptoms can increase the risk of stroke - a blockage in a major blood vessel in the brain, which can potentially result in a disability or even death. The objective of this study is to establish the feasibility of using ambulatory heart rate monitoring to determine the total incidence of atrial fibrillation in the peri-operative period before and after anatomic lung resection for malignancies. The study will also investigate the correlation between atrial fibrillation and rates of stroke and other adverse events, as well as serve to identify the patients that are at a higher risk of developing atrial fibrillation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atrial Fibrillation | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Stroke | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| iRhythm ZIO XT patch | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- iRhythm ZIO XT patch group
- description
- This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure
- interventionNames
- Device: iRhythm ZIO XT patch
Primary outcomes (4)
- measure
- Monthly rate of patient accrual
- timeFrame
- Ongoing from date of study initiation through to sample size completion, estimated to be 12 months
- description
- Proportion of patients who are determined to be eligible for study relative to the number of patients actually enrolled and consented for participation in the study. This will help to inform the willingness of patients to participate in this study
- measure
- Patient adherence to monitoring device use-Wear time
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be at least 18 years of age and competent to consent * Patients must be diagnosed with resectable lung cancer or metastatic lung disease eligible to complete metastasectomy * Patients must have one of: Male gender, age greater than 65, hypertension, obesity, and recent tobacco use within the past year * Patients must be booked for pneumonectomy, lobectomy or anatomical segmentectomy resection. Exclusion Criteria: * Patients undergoing emergent lung resection * Patients undergoing lung resection for non-oncologic indications (lung biopsy, bullectomy) * Patients with an existing neurostimulator * Patients with pre-existing cardiac disease, defined as: * Patients with atrioventricular blockage of any degree or sick sinus syndrome; * Patients with known previous atrial fibrillation or flutter lasting more than 1 month; * Patients with any persistent diagnosed preoperative arrhythmia * Patients with implanted external defibrillators or pacemakers * Patients with known adhesive allergies * Inability to comply with or understand ambulatory monitoring.
References
Publications (0)
Data not yet available